Sector News

Roche buys into Smarticles tech with GeneWEAVE deal

August 13, 2015
Life sciences
Roche is beefing up its microbiology offering with the purchase of US-based, privately-held in vitro diagnostics group GeneWEAVE BioSciences.
 
The move secures the Swiss drugs giant access to GeneWEAVE Smarticles technology, an innovative class of molecular diagnostics that quickly identifies multidrug-resistant organisms and assesses antibiotic susceptibility directly from clinical samples. 
 
“This technology has the potential to provide healthcare professionals access to quick and accurate diagnoses that can lead to rapid, informed treatment decisions,” said Roland Diggelmann, Roche Diagnostics’ chief operating officer.
 
Roche is paying GeneWEAVE shareholders $190 million upfront and up to $235 million in contingent product related milestones under the deal, which remains subject to all the usual closing conditions.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach